STAAR SURGICAL CO - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 29, 2000. STAAR SURGICAL CO is a medical device company specializing in intraocular lenses (IOLs) and related surgical equipment. The reporting period was marked by a significant restructuring plan announced in June 2000, management changes, and a private placement of equity to improve liquidity.
Key Financial Metrics
| Metric | Three Months Ended Sep 29, 2000 | Nine Months Ended Sep 29, 2000 | Nine Months Ended Oct 1, 1999 |
|---|---|---|---|
| Total Revenues | $13.66 million | $40.65 million | $43.38 million |
| Gross Profit | $8.31 million (60.8% margin) | $19.69 million (48.4% margin) | $27.17 million (62.6% margin) |
| Operating Income (Loss) | $1.05 million | $(19.38) million | $4.20 million |
| Net Income (Loss) | $0.54 million | $(17.71) million | $1.88 million |
| Cash and Equivalents (End of Period) | $21.76 million | ||
| Total Debt (Current + Long-term) | $21.81 million | ||
| Current Ratio | 1.6:1 |
Material Changes vs. Prior Period
- Revenue Decline: Nine-month revenues decreased 6.3% year-over-year due to lower unit sales of silicone IOLs in Asia and Europe and a stronger U.S. dollar. This was partially offset by sales of new FDA-approved Toric and Collamer IOLs.
- Restructuring Charges: The company recorded a pre-tax special charge of approximately $24 million in the second quarter of 2000. This included $5.2 million in inventory write-downs, $4.0 million in patent write-offs, and a $4.5 million write-off of the Japanese joint venture investment.
- Profitability Impact: The restructuring charges drove a net loss of $17.71 million for the nine-month period, compared to a net income of $1.88 million in the prior year. Gross margins compressed significantly (from 62.6% to 48.4%) primarily due to the inventory write-offs.
- Liquidity Improvement: Cash and cash equivalents increased by $18.4 million to $21.76 million, driven by a private placement of 1.5 million shares for $21.0 million (with $18.0 million received by quarter-end).
Guidance, Outlook, and Risks
- Outlook: Management expects to remain profitable in the future, relying on cash generated from operations or additional financing. Cost reduction programs initiated in manufacturing are expected to yield benefits early in the next fiscal year.
- Debt Restructuring: The company was not in compliance with certain restrictive covenants of its loan agreement during the first and second quarters. It obtained forbearance until October 31, 2000. Subsequent to the quarter, the company paid off all term debt and renegotiated its line of credit to a maximum of $7.0 million, due April 1, 2001.
- Legal Proceedings:
- Canon Dispute: Ongoing arbitration with Canon Inc. regarding the Japanese joint venture. Canon alleges breach of contract; Staar has filed a counterclaim alleging unfair dealings.
- Executive Litigation: Former CEO John R. Wolf has filed a lawsuit regarding stock options and property. The company intends to defend vigorously.
- Settlement: A settlement was reached with former EVP Vladimir Feingold for $600,000 plus stock option exercise.
- Management Changes: CEO John R. Wolf was terminated in May 2000. Interim CEO William C. Huddleston resigned subsequent to the quarter, and Chairman Andrew Pollet assumed the role temporarily.
Investor Verification Checklist
- Debt Covenants: Verify the status of the new $7.0 million line of credit and compliance with the new restrictive covenants effective post-quarter.
- Inventory Valuation: Assess the remaining inventory levels ($19.6 million) and the sustainability of gross margins following the $5.2 million write-down.
- Legal Exposure: Monitor the outcome of the arbitration with Canon Inc. and the litigation with former CEO John R. Wolf, as these could result in significant financial liability or operational disruption.
- Revenue Mix: Track the adoption rates of the new Toric and Collamer IOLs to determine if they can offset the decline in traditional silicone IOL sales.
- Management Stability: Confirm the appointment of a permanent CEO to replace the interim leadership.